Naloxone

Generic Name: Naloxone

Brand Names: Kloxxado, Narcan, Suboxone, Targin, Targiniq, Zimhi, Zubsolv, Nyxoid

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₂₁NO_₄

CAS Number: 465-65-6

Unique Ingredient Identifier: 36B82AMQ7N

Background: Naloxone is an opioid antagonist medication used to block or reverse the effects of opioid drugs, particularly within the setting of drug overdoses which are rapidly becoming a leading cause of death worldwide. More specifically, naloxone has a high affinity for μ-opioid receptors, where it acts as an inverse agonist, causing the rapid removal of any other d...

Indication: Naloxone nasal sprays are indicated for the reversal of an opioid overdose or suspected opioid overdose: it is intended for immediate administration as emergency therapy in settings where opioids may be present. Intramuscular, intravenous, and subcutaneous injections are indicated for complete or partial reversal of opioid depression, diagnosis of known or s...

Associated Conditions: Opioid Dependence, Opioid Overdose, Pruritus, Respiratory Depression, Septic Shock, Severe Pain, Moderate Pain, Suspected Opioid Overdose

Associated Therapies: Emergency Care

Clinical Trials

The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus

Phase 4

Terminated

Conditions: Fusion of Spine
Ileus

Interventions: Drug: Naloxone

First Posted Date: 2017-06-05

Last Posted Date: 2024-07-01

Lead Sponsor: Loyola University

Target Recruit Count: 53

Registration Number: NCT03176316

Locations: 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

Sensory and Opioid Mechanisms of Affective Touch

Early Phase 1

Completed

Conditions: Pain
Touch

Interventions: Other: Placebo
Drug: Naloxone

First Posted Date: 2017-03-30

Last Posted Date: 2021-07-30

Lead Sponsor: National Center for Complementary and Integrative Health (NCCIH)

Target Recruit Count: 29

Registration Number: NCT03096353

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health

Not Applicable

Completed

Conditions: Endogenous and Esophageal Sensitivity

Interventions: Other: Placebo
Drug: Naloxone
Drug: Methylnaltrexone Bromide

First Posted Date: 2017-01-09

Last Posted Date: 2017-01-09

Lead Sponsor: Universitaire Ziekenhuizen KU Leuven

Target Recruit Count: 12

Registration Number: NCT03014843

Effect of High-dose Naloxone Following Third Molar Extraction

Phase 2

Completed

Conditions: Healthy Subjects
Pain, Acute
Sensitization, Central
Hyperalgesia
Inflammations, Endodontic

Interventions: Drug: Naloxone
Drug: Normal Saline

First Posted Date: 2016-11-29

Last Posted Date: 2024-02-22

Lead Sponsor: mads u werner

Target Recruit Count: 23

Registration Number: NCT02976337

Locations: 🇩🇰
Neuroscience Center, Copenhagen University Hospital, Copenhagen, Denmark

The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.

Phase 4

Completed

Conditions: Respiratory Depression

Interventions: Drug: Placebo
Drug: Naloxone

First Posted Date: 2016-09-01

Last Posted Date: 2017-12-19

Lead Sponsor: University College Dublin

Target Recruit Count: 96

Registration Number: NCT02885948

Locations: 🇮🇪
Prof. Alistair Nichol, Dublin, Ireland

The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study

Not Applicable

Completed

Conditions: Pain

Interventions: Drug: High dose Remifentanil
Drug: Low dose remifentanil
Drug: Normal Saline
Drug: Naloxone

First Posted Date: 2016-08-04

Last Posted Date: 2016-11-16

Lead Sponsor: Seoul National University Hospital

Target Recruit Count: 92

Registration Number: NCT02856087

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Biology and Experience of Eating in Women With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: Naloxone
Drug: Placebo

First Posted Date: 2016-06-20

Last Posted Date: 2021-11-03

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 41

Registration Number: NCT02805972

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States

Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study

Phase 1

Conditions: Drug Overdose
Opioid-Related Disorders

Interventions: Drug: Naloxone

First Posted Date: 2016-04-12

Last Posted Date: 2016-05-17

Lead Sponsor: King's College London

Target Recruit Count: 4

Registration Number: NCT02733822

Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury

Phase 2

Completed

Conditions: Healthy Subjects

Interventions: Drug: Normal saline
Drug: Naloxone

First Posted Date: 2016-02-18

Last Posted Date: 2024-02-23

Lead Sponsor: mads u werner

Target Recruit Count: 80

Registration Number: NCT02684669

Locations: 🇩🇰
Neuroscience Center, Copenhagen University Hospital, Copenhagen, Denmark

Naloxone for Optimizing Hypoxemia Of Lung Donors

Phase 2

Completed

Conditions: Lung Transplantation
Brain Death
Organ Donors

Interventions: Drug: Naloxone
Drug: Normal saline

First Posted Date: 2015-10-20

Last Posted Date: 2020-07-31

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 199

Registration Number: NCT02581111

Locations: 🇺🇸
Lifeline of Ohio, Columbus, Ohio, United States
🇺🇸
Donor Alliance, Denver, Colorado, United States
🇺🇸
Louisiana Organ Procurement Agency, Metairie, Louisiana, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy